Skip to content

Study · Animal study (in vivo) · mouse · 2011

4 results

Comparison of exendin-4 on beta-cell replication in mouse and human islet grafts.

Tian L, Gao J, Weng G, Yi H, Tian B, O'Brien TD, Guo Z

Transplant international : official journal of the European Society for Organ Transplantation1 Jun 2011Cited by 39 (Europe PMC)

PMID21627696 (opens in a new tab)DOI10.1111/j.1432-2277.2011.01275.x (opens in a new tab)PepBankPUB-21627696
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice with syngeneic mouse islet grafts, exendin‑4 accelerated normoglycemia compared with untreated mice.

    In plain wordsIn mice with mouse islet grafts, exendin‑4 restored normal glucose faster than no treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseTime to normoglycemia
    Study

    mousen: not reported in source

    diabetic mice with islet grafts
    Comparator
    untreated mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 4 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Although diabetes was reversed in all mice transplanting syngeneic mouse islets from young or old donors, normoglycemia was achieved significantly faster in exendin-4 treated mice.
    2 context sentences
    Summary · context
    Islets, isolated from mouse and human donors at different ages, were transplanted into diabetic mice and/or diabetic nude mice that were given bromodeoxyuridine (BrdU) with or without exendin-4.
    Summary · context
    At 4 weeks post-transplantation, islet grafts were removed for insulin and BrdU staining and quantification of insulin(+)/BrdU(+) cells.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with mouse islet grafts, exendin‑4 increased insulin-positive, BrdU-positive beta cells compared with untreated mice.

    In plain wordsIn mice with mouse islet grafts, exendin‑4 increased the beta-cell replication marker compared with no treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseMouse graft beta-cell replication
    Study

    mousen: not reported in source

    diabetic mice with islet grafts
    Comparator
    untreated mice
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated · 4 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Mouse islet grafts in exendin-4 treated mice had significantly more insulin(+)/BrdU(+) β cells than in untreated mice (P < 0.01).
    2 context sentences
    Summary · context
    Islets, isolated from mouse and human donors at different ages, were transplanted into diabetic mice and/or diabetic nude mice that were given bromodeoxyuridine (BrdU) with or without exendin-4.
    Summary · context
    At 4 weeks post-transplantation, islet grafts were removed for insulin and BrdU staining and quantification of insulin(+)/BrdU(+) cells.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with human islets from donors aged ≤22 years, exendin‑4 increased labeled beta cells compared with untreated mice.

    In plain wordsIn mice with young human donor islets, exendin‑4 increased the beta-cell replication marker compared with no treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseYoung human donor graft beta-cell replication
    Study

    mousen: not reported in source

    diabetic mice with islet grafts
    Comparator
    untreated mice
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated · 4 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Human islet grafts from ≤22-year-old donors had more insulin(+)/BrdU(+) β cells in exendin-4 treated mice than that in untreated mice (P < 0.01).
    2 context sentences
    Summary · context
    Islets, isolated from mouse and human donors at different ages, were transplanted into diabetic mice and/or diabetic nude mice that were given bromodeoxyuridine (BrdU) with or without exendin-4.
    Summary · context
    At 4 weeks post-transplantation, islet grafts were removed for insulin and BrdU staining and quantification of insulin(+)/BrdU(+) cells.

Studies that did not test the peptide alone1

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 04AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome

    In mice with human islets from donors aged ≥35 years, few labeled beta cells occurred with or without exendin‑4.

    In plain wordsIn mice with older human donor islets, few beta cells showed the replication marker with or without exendin‑4.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Direction not reportedOlder human donor graft beta-cell replication
    Study

    mousen: not reported in source

    diabetic mice with islet grafts
    Comparator
    untreated mice
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    However, human islet grafts from ≥35-year-old donors contained few insulin(+)/BrdU(+) β cells in exendin-4 treated or untreated mice.
    2 context sentences
    Summary · context
    Islets, isolated from mouse and human donors at different ages, were transplanted into diabetic mice and/or diabetic nude mice that were given bromodeoxyuridine (BrdU) with or without exendin-4.
    Summary · context
    At 4 weeks post-transplantation, islet grafts were removed for insulin and BrdU staining and quantification of insulin(+)/BrdU(+) cells.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.